About Zymeworks
Zymeworks is a company based in Vancouver (Canada) founded in 2003. It operates as a Professional Services. Zymeworks has raised $145.97 million across 15 funding rounds from investors including Lilly, Northleaf and Celgene. The company has 286 employees as of December 31, 2024. Zymeworks has completed 1 acquisition, including Kairos Therapeutics. Zymeworks offers products and services including ZW1528 and ZW171. Zymeworks operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Vancouver, Canada
- Employees 286 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Zymeworks Inc.
-
Annual Revenue
$76.3 M (USD)0.38as on Dec 31, 2024
-
Net Profit
-$122.7 M (USD)-3.39as on Dec 31, 2024
-
EBITDA
-$108.63 M (USD)10.04as on Dec 31, 2024
-
Total Equity Funding
$145.97 M (USD)
in 15 rounds
-
Latest Funding Round
$50 M (USD), Post-IPO
Dec 26, 2023
-
Investors
Lilly
& 13 more
-
Employee Count
286
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Zymeworks
Zymeworks is a publicly listed company on the NASDAQ with ticker symbol ZYME in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Zymeworks
Zymeworks offers a comprehensive portfolio of products and services, including ZW1528 and ZW171.
Preclinical data on ZW1528 is presented for respiratory research.
Development of ZW171 was discontinued for mesothelin targeting.
People of Zymeworks
Unlock access to complete
Unlock access to complete
Leadership Team
20 people
Software Development Team
10 people
Finance and Accounting
10 people
Senior Team
6 people
Legal and Compliance
4 people
Manager Team
3 people
Product Management Team
3 people
Data Analysis and Operations Team
3 people
Unlock access to complete
Funding Insights of Zymeworks
Zymeworks has successfully raised a total of $145.97M across 15 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Zymeworks
Zymeworks has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Northleaf and Celgene.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in life sciences companies.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Diversified investment management is conducted by Teralys Capital.
|
Locked | Locked | Locked |
Investor details for Zymeworks
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Zymeworks
Zymeworks has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Kairos Therapeutics.
Investment portfolio details for Zymeworks
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
An antibody-drug conjugate platform is developed for cancer treatments.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Zymeworks
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Zymeworks
Detailed financials for Zymeworks
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Zymeworks Comparisons
Peer comparison for Zymeworks
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Zymeworks
Zymeworks operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
Detailed competitors of Zymeworks
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Zymeworks
Complete news archive for Zymeworks
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zymeworks
Zymeworks was founded in 2003 and raised its 1st funding round 2 years after it was founded.
Zymeworks is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Zymeworks is a funded company, having raised a total of $145.97M across 15 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Zymeworks is 286.
Annual revenue of Zymeworks is $76.3M as on Dec 31, 2024.
Novel biotherapeutics are engineered by Zymeworks to address difficult-to-treat cancers and other serious diseases. A fully integrated RD engine is utilized, spanning target selection to pivotal studies, supported by world-class researchers. Focus is placed on areas with high unmet medical needs, leveraging antibody-drug conjugates and multispecific antibody therapeutics technology platforms. A growing pipeline of multifunctional therapeutics is maintained to deliver transformational therapies globally through partnerships and collaborations.
Zymeworks's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Zymeworks offers ZW1528 and ZW171.
Yes, Zymeworks is publicly traded on NASDAQ under the ticker symbol ZYME.
Zymeworks has made 1 acquisition, including Kairos Therapeutics.
Zymeworks has 14 investors. Key investors include Lilly, Northleaf, Celgene, Perceptive Advisors, and EcoR1.
The ticker symbol of Zymeworks is ZYME on NASDAQ.